← All trials
NCT05564390
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 28, 2023
- Primary completion
- May 12, 2032
- Completion date
- May 12, 2032
- First posted
- Oct 3, 2022
- Last posted
- Nov 9, 2022
- Enrollment
- 750
- Arms / groups
- 12 / —
- Source
- AACT · ctgov ingestion
Sponsors
- National Cancer Institute (NCI)Lead sponsor
- Southwest Oncology GroupOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.